Qube Research & Technologies LTD Voyager Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$7.15 - $10.84 $191,262 - $289,970	-26,750 Reduced 78.3%	7,413 $69,000
Q4 2023 Feb 13, 2024	SELL	$6.28 - $8.81 $401,417 - $563,135	-63,920 Reduced 65.17%	34,163 $288,000
Q3 2023 Nov 13, 2023	BUY	$7.55 - $11.25 $740,526 - $1.1 Million	98,083 New	98,083 $760,000
Q1 2023 May 15, 2023	BUY	$6.0 - $10.78 $315,024 - $565,993	52,504 Added 176.06%	82,326 $634,000
Q4 2022 Feb 14, 2023	BUY	$4.94 - $6.61 $23,015 - $30,795	4,659 Added 18.52%	29,822 $181,000
Q3 2022 Nov 14, 2022	BUY	$5.57 - $7.47 $36,450 - $48,883	6,544 Added 35.15%	25,163 $149,000
Q2 2022 Aug 15, 2022	BUY	$4.82 - $10.09 $89,743 - $187,865	18,619 New	18,619 $110,000

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $207M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.